Physician profile
Benjamin Herrick
NPI 1588838965
$3,643.43
in general payments reported to CMS, 2019-2025
29 companies · $628 in 2025
The $628 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $158 · 2021: $54.47 · 2022: $671 · 2023: $311 · 2024: $1,149 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509 · Travel and Lodging: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.86 |
| Travel and Lodging | $578.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $941.62 | 2023-2025 | Upsylon, Advantage System, Solyx Sis System |
| Astellas Pharma US INC | $477.55 | 2019-2025 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $352.77 | 2019-2024 | Provenge |
| Janssen Biotech, INC. | $350.50 | 2019-2025 | Rybrevant, Carvykti, Balversa |
| Pfizer INC. | $193.28 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $189.02 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $140.70 | 2022-2024 | Jelmyto |
| Merck Sharp & Dohme LLC | $125.63 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $114.57 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $97.19 | 2022-2023 | Xiaflex, Aveed |
| Abbvie INC. | $86.83 | 2022-2025 | |
| Blue Earth Diagnostics | $66.05 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $63.33 | 2022-2025 | Lynparza |
| Myovant Sciences INC. | $62.27 | 2022 | |
| Amgen INC. | $57.13 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.24 | 2025 | |
| Bioprotect Medical, INC. | $43.64 | 2025 | Bioprotect Balloon Implant System |
| Myriad Genetic Laboratories, INC. | $30.16 | 2022-2024 | Prolaris |
| Antares Pharma, INC. | $28.33 | 2019-2020 | |
| Coloplast Corp | $22.84 | 2025 | |
| Urovant Sciences INC | $21.79 | 2022 | |
| Ethicon US, LLC | $20.29 | 2024 | Enseal |
| Sun Pharmaceutical Industries INC. | $19.67 | 2022 | |
| Laborie Medical Technologies Corp. | $17.68 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Progenics Pharmaceuticals, INC. | $17.26 | 2022 | |
| Verity Pharmaceuticals INC. | $13.78 | 2025 | Trelstar |
| Procept Biorobotics Corporation | $13.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.98 | 2023 | |
| Ferring Pharmaceuticals INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Herrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.